Liraglutide vs Brenipatide
A once-daily GLP-1 receptor agonist; an earlier acylated analog. A once-monthly dual GIP/GLP-1 agonist aimed at the brain's reward circuitry rather than the scale. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Liraglutide | Brenipatide LY3537031 | |
|---|---|---|
| Also known as | Victoza, Saxenda | — |
| Type | Analog | Analog |
| Evidence | Established | Investigational |
| Family | Incretins & metabolic | Incretins & metabolic |
| Class | GLP-1 receptor agonist (acylated, 31 aa) | GIP/GLP-1 dual agonist (acylated peptide) |
| Receptor | GLP-1 receptor (GLP-1R) | GIP + GLP-1 receptors |
| Molecular weight | ~3,751.2 Da | ≈4,900 Da |
| Half-life | engineered for once-monthly dosing | |
| Based on | Glucagon-like peptide-1 | Glucagon-like peptide-1 |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Liraglutide and Brenipatide?
- Liraglutide is an engineered analog based on Glucagon-like peptide-1; Brenipatide is an engineered analog based on Glucagon-like peptide-1. Liraglutide signals at GLP-1 receptor (GLP-1R); Brenipatide signals at GIP + GLP-1 receptors.
- How do the half-lives of Liraglutide and LY3537031 compare?
- The reported circulating half-life of Liraglutide is ~13 h; Brenipatide is engineered for once-monthly dosing. These are reference values for the native or representative form — educational only, not dosing advice.
- Is Liraglutide the same as Victoza?
- Victoza, Saxenda are brand names of Liraglutide. This comparison describes the molecules, not branded products.
Prefer the other order? Brenipatide vs Liraglutide. Or open the interactive comparison tool to add more molecules.